ABBVIE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Phase 3
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 184
- Registration Number
- NCT02265237
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Phase 3
Completed
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 595
- Registration Number
- NCT02264990
- Locations
- 🇨🇿
Multiscan s.r.o. /ID# 132689, Pardubice, Czechia
🇩🇪Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany
🇹🇷Inonu University /ID# 136569, Malatya, Turkey
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 160
- Registration Number
- NCT02247401
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Phase 2
Completed
- Conditions
- HCVHepatitis C VirusChronic Hepatitis C
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT02243280
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Phase 2
Completed
- Conditions
- Hepatitis C VirusChronic Hepatitis C
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 694
- Registration Number
- NCT02243293
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 19
- Registration Number
- NCT02220738
- Locations
- 🇺🇸
Site Reference ID/Investigator# 129545, Glendale, California, United States
🇺🇸Site Reference ID/Investigator# 129435, Orlando, Florida, United States
🇺🇸Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
Phase 3
Completed
- Conditions
- Chronic Hepatitis C InfectionCompensated Cirrhosis
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT02219503
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Phase 3
Completed
- Conditions
- Chronic Hepatitis CDecompensated CirrhosisHepatitis C Virus
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02219477
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1596
- Registration Number
- NCT02219490
- Locations
- 🇳🇴
Akershus Universitetssykehus_MAIN /ID# 132212, Lorenskog, Akershus, Norway
🇩🇰Odense University Hospital /ID# 131029, Odense C, Syddanmark, Denmark
🇩🇰Aarhus Univ Hospital, Skejby /ID# 131030, Aarhus, Denmark
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02216422
© Copyright 2025. All Rights Reserved by MedPath